Cancer diagnostics is an umbrella term that encompasses all diagnostics modalities such as imaging, molecular diagnostics, and biopsy employed in drawing conclusions regarding cancer diagnosis and ...
Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease is a rare, progressive, and fatal neuromuscular disease characterized by degeneration of upper and lower motor neurons. While it is associated with a mortality rate of 50% within 30 months of Amyotrophic Lateral Sclerosis symptoms onset, there is still no ...
Find More
Enhertu with Opdivo exhibited clinical efficacy with an ORR of 36.7% in HER2+ urothelial cancer in Phase Ib study On the second day of ASCO-GU 2022, the rapid abstract session highlighted the results from the DS8201-A-U105 trial (NCT03523572; Active, not recruiting) of Enhertu (trastuzumab deruxtecan) with Opdiv...
Find More
Chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates are being used for treating Urothelial Carcinoma(UC) patients and now PARP inhibitors are being studied in UC in the neoadjuvant, first-line, maintenance therapy, and subsequent lines of the setting. It is worth n...
Find More
Osteosarcoma and Ewing sarcoma are two of the most common malignancies of bone tissues present in children. Osteosarcoma treatment usually involves surgery and chemotherapy and Ewing sarcoma treatment typically begins with chemotherapy only. Dr. James Ewing who described the tumor in the 1920’s distinguished the tu...
Find More
Phase II study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma Based on the findings from the Phase II study (NCT04022343), neoadjuvant cabozantinib was safe and induced a reduction in tumor size in all patients with locally advanced nonmetastatic ccRC...
Find More
Padcev (Enfortumab vedotin) for the treatment of locally advanced or metastatic urothelial cancer, Adcetris (Brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas, and Tivdak (Tisotumab vedotin) for the treatment of recurrent or metastatic cervical cancer are the three ADCs that Seage...
Find More
Parkinson's disease (PD) is the second most prevalent neurogenerative disorder, with a growing global prevalence due to population aging. Despite increased awareness and significant research advancement, Parkinson’s disease treatment options include dopamine replacement therapy, symptomatic therapies that have sign...
Find More
Use of CAR-T treatments and their efficacy in Prostate Cancer We already know that Immunotherapies have not performed well in the treatment of prostate cancer. Such medicines have failed to elicit a long-term response in patients with advanced prostate cancer. Surgery, radiation treatment, chemotherapy, androgen...
Find More
Major Key player Arvinas announced completed Phase I and interim Phase II ARDENT data for ARV-110 degrader targeting the androgen receptor (AR). According to the results, Arvinas mentioned that at the data cut-off date, December 20, 2021, the PSA50 response rate was 46% in 28 patients with AR T878X/H875Y tumor muta...
Find More
Acromegaly is a rare, slowly progressive disorder that is caused when the pituitary glands produce t.....
Find More
Systemic Lupus Erythematosus (SLE) is an autoimmune disease where the immune system of the body mist.....
Find More
Cancer, an immunologic condition that can begin in any organ or tissue of the body is the second lea.....
Find More
An autosomal recessive disorder, Ataxia Telangiectasia, affects a person's nervous system, immune sy.....
Find More
Advances in continuous glucose monitoring (CGM) has led to a paradigm shift in the management of typ.....
Find More
Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, whic.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
